TENX stock icon

Tenax Therapeutics
TENX

$3.36
2.92%

Market Cap: 6.58M

 

About: Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Employees: 5

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

5.22% less ownership

Funds ownership: 5.63% [Q4 2023] → 0.41% (-5.22%) [Q1 2024]

53% less funds holding

Funds holding: 17 [Q4 2023] → 8 (-9) [Q1 2024]

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

92% less capital invested

Capital invested by funds: $368K [Q4 2023] → $30.5K (-$337K) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$30
793%
upside
Avg. target
$30
793%
upside
High target
$30
793%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Roth MKM
Jonathan Aschoff
793%upside
$30
Buy
Reiterated
20 Feb 2024

Financial journalist opinion